R&D
September 15, 2011
Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor
Clin Cancer Res., 2011, 17:18, 5962-5972
September, 2011
Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use.
Biotechnol Bioeng., 2011, 108:9, 2171-2181
February, 2011
Capturing the natural diversity of the human antibody response against vaccinia virus.
J.Virology, 2011, 85:4, 1820-1833
August 6, 2010
January, 2010
Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Cancer Research, 2010, 70, 588-597